Skip to main content
. 2022 Sep 12;8(5):e200011. doi: 10.1212/NXG.0000000000200011

Figure 2. Survival Analyses of FUS Carriers.

Figure 2

(A) Survival analysis of early-onset FUS carriers (age at onset younger than 46 years, left) and mid-to-late onset FUS (older than 46 years, right) vs nonmutated ALS cases. Early-onset FUS median survival 82.7 weeks (IQR 47.9–95.9) and non-FUS early-onset ALS median survival 204.7 weeks (IQR 126.1–274.0); log-rank p-value = 0.000006. Mid-to-late onset FUS median survival 126.1 (IQR 86.7–195.6) and non-FUS mid-to-late onset ALS median survival 121.9 (78.1–195.6); log-rank p-value = 0.2 (B) Survival analysis of early-onset FUS carriers (age at onset <46 years) vs mid-to-late onset FUS (>46 years). ALS = amyotrophic lateral sclerosis; FUS = fused in sarcoma.